SEC Form 4 · accession 0000899243-15-002783

Aimmune Therapeutics, Inc. · AIMT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

Director · 10% Owner

10% Owner

10% Owner

10% Owner

Period of report

Aug 11, 2015

Accepted (ET)

Aug 11, 2015 · 11:49 am EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001631650

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, $0.0001 par value^F1,F2	Aug 11, 2015	C	3,873,530	—	A	3,873,530	I	By: Longitude Venture Partners II, L.P.
Common Stock, $0.0001 par value^F1,F2	Aug 11, 2015	C	3,248,600	—	A	7,122,130	I	By: Longitude Venture Partners II, L.P.
Common Stock, $0.0001 par value^F2	Aug 11, 2015	P	312,500	$16.00	A	7,434,630	I	By: Longitude Venture Partners II, L.P.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Convertible Preferred Stock^F1,F2,F4	—	Aug 11, 2015	C	3,873,530	D	—	—	Common Stock	3,873,530	0	I
Series B Convertible Preferred Stock^F1,F2,F4	—	Aug 11, 2015	C	3,248,600	D	—	—	Common Stock	3,248,600	0	I

F1The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1 for 1 basis immediately prior to the closing of Issuer's initial public offering.
F2This report is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. Longitude Capital II as general partner of Longitude Venture II maybe deemed to have sole voting, investment and dispositive power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are each managing members of Longitude Capital II and in their capacity as such, may be deemed to exercise shared voting and investment power over the shares held by Reporting Persons. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.
F3Longitude Capital II purchased an additional 312,500 shares of Issuer's common stock in connection with the initial public offering at the offering price of $16.00 per share.
F4The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock have no expiration date.